RECEIVABLES	3 Months Ended
Mar. 31, 2016
Receivables [Abstract]
RECEIVABLES	RECEIVABLES Trade Receivables Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was $13.4 million and $12.5 million at March 31, 2016 and December 31, 2015, respectively. The total reserves for both periods were immaterial. Notes Receivables Notes receivable arose from the sale by the Company of a pediatric priority review voucher ("PRV") in July 2015 to Sanofi for $245.0 million. $150.0 million was received upon closing, and $47.5 million is due on each of the first and second anniversaries of the closing. In accordance with GAAP, the Company recorded the future short term and long term notes receivable at their present value of $46.2 million and $44.9 million, respectively, at the date of the sale using a discount rate of 2.8%. The accretion on the notes receivable totaled $0.6 million and is recorded in interest expense, net, in the Consolidated Statements of Operations and Comprehensive Income for the three month period ending March 31, 2016. The present value of the current and long-term notes receivable was $47.2 million and $45.9 million, and $46.8 million and $45.6 million, as of March 31, 2016 and December 31, 2015, respectively. The Company noted no indications for impairment as of March 31, 2016.

RECEIVABLES

3 Months Ended

Mar. 31, 2016

Trade Receivables

Accounts receivable, net of reserves for prompt pay discounts and doubtful accounts, was $13.4 million and $12.5 million at March 31, 2016 and December 31, 2015, respectively. The total reserves for both periods were immaterial.

Notes Receivables

Notes receivable arose from the sale by the Company of a pediatric priority review voucher ("PRV") in July 2015 to Sanofi for $245.0 million. $150.0 million was received upon closing, and $47.5 million is due on each of the first and second anniversaries of the closing. In accordance with GAAP, the Company recorded the future short term and long term notes receivable at their present value of $46.2 million and $44.9 million, respectively, at the date of the sale using a discount rate of 2.8%. The accretion on the notes receivable totaled $0.6 million and is recorded in interest expense, net, in the Consolidated Statements of Operations and Comprehensive Income for the three month period ending March 31, 2016. The present value of the current and long-term notes receivable was $47.2 million and $45.9 million, and $46.8 million and $45.6 million, as of March 31, 2016 and December 31, 2015, respectively. The Company noted no indications for impairment as of March 31, 2016.